1. Home
  2. Technology

TECHNOLOGY

Advancing Health through Technology


Driving acceleration of innovative technologies into healthcare diagnostic testing

Camtech is dedicated to advancing biomedical research and human health. Recognizing the need to innovate unceasingly, we are constantly developing new technologies to transform healthcare diagnostics and biomedical research. Our present capabilities in microfluidics systems, automation platforms, and bioimaging capabilities are just the beginning. Alongside our developments in lateral flow assays and digital health, we are well-positioned to provide cutting-edge diagnostics and research tools for life science and medical hubs worldwide.

CamPrep Automated platform for Next Generation Sequencing

Next-generation sequencing (NGS) is a powerful genetic laboratory process, but also a laborious multi-step process where errors can abound. The many steps required to prepare libraries for NGS and the microliter or nanoliter volumes render the workflow highly sensitive to technical errors. Sequencing centres, diagnostic labs, and hospitals sequence thousands of samples daily, and streamlining NGS protocols would significantly ease manpower requirements as they prepare NGS libraries.

We have harnessed microfluidic automation to make preparing NGS libraries easy and scalable. With a consortium of research partners from the EU and USA, Camtech is developing a novel microfluidics device using our electrowetting platform. With it, we can manipulate the flow of liquid droplets on a surface, enabling the automation of DNA extraction and library preparation from clinical samples. This technology allows the personalisation of library processing protocols on microfluidic chips through robust downscaling.

As part of the DRAIGON project and working with the European Vaccine Initiative, we are developing this disruptive microfluidic application to make tracking antimicrobial resistance (AMR) genes and strains much easier, more effective, and more economical.
READ MORE

Optical imaging

Bioluminescence imaging (BLI) provides a sensitive, safe, and simple approach to study host responses to therapeutics. Luciferases and luciferins act as the backbone to BLI. However, existing luciferases are sensitive to low pH and have weak thermal and spectral stability. Blood components, such as haemoglobin, also quench optical signals in the visible range, making biological processes more difficult to detect with luciferins.

We have partnered with Bioflares Ltd, which has engineered a patented toolbox of infraluciferases and infraluciferins, to bring this powerful and promising solution to market to enable preclinical research imaging. This combination of infraluciferases and infraluciferins is the first of its kind to emit light within the near-infrared region. With its doubled spectral range, BLI signals become easier to detect across diverse cell types, providing the potential to investigate cellular anatomy and physiology in in vitro and in vivo models.

Microfluidics

To minimise reagent use, increase sensitivity and throughput, biochemical or biosensing processes often feature volumes in the micro-, nano-, and picoliter ranges that significantly increase the risk of technical error.

Microfluidics can miniaturise volumes within a small, yet controlled system, achieving multiplexing, automation and reproducible high throughput screening, amongst other applications.

We have a patented approach to concentrate blood cells and biomarkers at sub-femtomolar concentrations (that’s 1/1000th of picomolar concentrations) that will significantly increase analyte concentration compatible with biosensors.

We are also developing automation solutions for sample-to-answer testing, sample preparation workflows, as well as microfluidic based platforms for detection of infectious diseases in blood and other clinical specimens.